S

SWK Holdings Corp
NASDAQ:SWKH

Watchlist Manager
SWK Holdings Corp
NASDAQ:SWKH
Watchlist
Price: 16.68 USD 0.18%
Market Cap: $201.8m

SWK Holdings Corp
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

SWK Holdings Corp
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
S
SWK Holdings Corp
NASDAQ:SWKH
Non-Reccuring Items
-$2.6m
CAGR 3-Years
N/A
CAGR 5-Years
-75%
CAGR 10-Years
2%
LM Funding America Inc
NASDAQ:LMFA
Non-Reccuring Items
-$563k
CAGR 3-Years
6%
CAGR 5-Years
20%
CAGR 10-Years
-8%
A-Mark Precious Metals Inc
NASDAQ:AMRK
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Standard Premium Finance Holdings Inc
OTC:SPFX
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SUI Group Holdings Ltd
NASDAQ:SUIG
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SWK Holdings Corp
Glance View

Market Cap
201.8m USD
Industry
Financial Services

SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.

SWKH Intrinsic Value
15.07 USD
Overvaluation 10%
Intrinsic Value
Price
S

See Also

What is SWK Holdings Corp's Non-Reccuring Items?
Non-Reccuring Items
-2.6m USD

Based on the financial report for Sep 30, 2025, SWK Holdings Corp's Non-Reccuring Items amounts to -2.6m USD.

What is SWK Holdings Corp's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 10Y
2%

Over the last year, the Non-Reccuring Items growth was 77%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett